Protara Therapeutics, Inc. short interest in 2024
In 2024, Protara Therapeutics, Inc.'s disclosed short interest ran from 0.65% of shares outstanding on 12 Jan 2024 to 24.72% on 31 Dec 2024, a change of +24.07 percentage points. The year's high was 26.21% on 13 Dec 2024 and its low 0.52% on 15 Feb 2024, averaging 9.17% across 16 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.30 days on 15 Oct 2024. Full history: Protara Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 0.65% (12 Jan 2024)
- End of year
- 24.72% (31 Dec 2024)
- Change
- +24.07 pp
- High
- 26.21% (13 Dec 2024)
- Low
- 0.52% (15 Feb 2024)
- Average
- 9.17%
- Highest days to cover
- 22.30 (15 Oct 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 0.65% | 1.07 | |
| 31 Jan 2024 | 0.78% | 1.64 | |
| 15 Feb 2024 | 0.52% | 1.00 | |
| 29 Feb 2024 | 0.69% | 1.00 | |
| 15 Mar 2024 | 0.54% | 1.00 | 10-K filed, results (8-K) |
| 28 Mar 2024 | 0.57% | 1.00 | |
| 15 Aug 2024 | 9.11% | 10.51 | 10-Q filed, results (8-K), 10-Q filed, results (8-K) |
| 30 Aug 2024 | 9.91% | 11.46 | |
| 13 Sep 2024 | 10.20% | 10.69 | |
| 30 Sep 2024 | 10.40% | 16.71 | |
| 15 Oct 2024 | 11.24% | 22.30 | |
| 31 Oct 2024 | 13.27% | 10.71 | |
| 15 Nov 2024 | 13.21% | 15.02 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 14.62% | 18.53 | |
| 13 Dec 2024 | 26.21% | 1.00 | |
| 31 Dec 2024 | 24.72% | 7.46 |
See also: Protara Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.